Hemispherx’s Alferon And Ampligen Effective Against Ebola Virus
http://www.bidnessetc.com/28451-hemispherxs-alferon-and-ampligen-effective-against-ebola-virus/
Ampligen inhibits human herpesvirus-6 in vitro.
http://www.ncbi.nlm.nih.gov/pubmed/7893986
New HHV-6 Research Suggests Additional Ampligen(R) Role in Treating CFS
http://www.prnewswire.com/news-releases/new-hhv-6-research-suggests-additional-ampligenr-role-in-treating-cfs-77022237.html
NEW YORK, Oct. 16 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB) said today that recently reported research that indicates Human Herpes Virus 6 (HHV-6) has a role in pathogenesis of Chronic Fatigue Syndrome (CFS) symptoms may further explain Ampligen's(R) potential role in treatment of the disorder. Earlier peer-reviewed studies from independent researchers associated with the National Institutes of Health (NIH), have shown that Ampligen can eradicate HHV-6 infection in vitro; Ampligen demonstrated the maximum antiviral activity from a large panel of approximately three dozen prospective antiviral/immunological drugs. The new HHV-6 research was presented in a paper this past week by Dr. D.V. Ablashi of Advanced Biotechnologies Inc. and Georgetown University School of Medicine, et. al., at the American Association for Chronic Fatigue Conference held in Cambridge, Massachusetts. Dr. Ablashi, who is a Board member of the national association, utilized specialized techniques to actually harvest live, replicating virus from a group of CFS patients. Dr. Ablashi's scientific abstract, entitled, "Increased Activation of Human Herpes Virus-6 (HHV-6) but not Human Herpes Virus-7 (HHV-7) or Human Herpes Virus-8 (HHV-8) in Chronic Fatigue Syndrome Patients" detected the active replicating HHV-6 in 57% of CFS patients versus only 8% of a normal healthy population. Hemispherx said that this new finding represents the second disease marker to be recently announced, and provides additional evidence for a possible Ampligen mechanism in treatment of CFS. As recently announced, the pioneering efforts of Dr. Robert Suhadolnik (U.S.), and subsequent researchers at Montpelier University (France) and the Free University of Brussels (Belgium) confirmed the identification of a specifically abnormal immune/antiviral factor, a natural disease barrier against many viruses, in the blood's immune cells from approximately 90% of CFS patients (now termed the "REDD" abnormality). Hemispherx said that while the proximate cause of CFS remains unknown, measuring of both HHV-6 replication and REDD may serve as powerful markers to evaluate the disease process itself. In this case, the active drug would function as a type of bifurcated warhead -- attacking both the replicating virus (HHV-6) as well as the REDD abnormality which led to the breakdown in host defense barriers. According to the National Institutes of Health, during the early years of life, HHV-6 infection is observed in 90% of the U.S. population, but antibodies and the intact immune system thereafter keep the virus in check and present only in dormant form. However, the dysfunctional immune system of many CFS sufferers thereafter allows the virus to awake from dormancy and renew its replication and growth. Currently, Ampligen is the only drug being developed worldwide for treatment of CFS at the Phase III clinical trial level. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE Hemispherx Biopharma, Inc.